摘要
癌基因cerbB2与乳腺癌的发生、发展密切相关,是乳腺癌的一个重要分子标志物和治疗靶。ErbB家族信号通路是一个非常复杂的网络系统,其异常激活可引起细胞生长增殖失控、恶性转化及肿瘤浸润转移。针对cerbB2的乳腺癌靶向治疗是近年来的研究热点,人源化抗cerbB2单克隆抗体Herceptin已经成功用于乳腺癌的临床治疗,pertuzumab、酪氨酸激酶抑制剂、cerbB2肽疫苗、腺病毒E1A基因治疗等均具有广阔的应用前景。现有的cerbB2检测方法中IHC和FISH较为常用,新涌现的一些检测方法如CISH、ELISA、RTPCR等亦各有优势,但仍需进一步完善。
The oncogene c-erbB-2 might play a critical role in both the initiation and progression of breast cancer. The signal transduction of ErbB family is a complex network regulating diverse biologic responses including proliferation, differentiation, cell motility, and survival. These findings lead to the development of antibodies that down-regulate c-erbB-2. Such a therapeutic approach has already been found effective in experimental tumor models and in clinical trials as well. c-erbB-2 testing is currently performed utilizing two main methods: IHC and FISH.New testing methods such as CISH、ELISA、RT-PCR all have broad future.
出处
《安徽医药》
CAS
2005年第6期407-410,共4页
Anhui Medical and Pharmaceutical Journal
